KDM1 is a novel therapeutic target for the treatment of gliomas
Gangadhara R. Sareddy(The University of Texas at San Antonio Health Science Center), Ratna K. Vadlamudi(The University of Texas at San Antonio Health Science Center), Takayoshi Suzuki(Nagoya City University), Vijay K. Gonugunta(The University of Texas at San Antonio Health Science Center), Naoki Miyata(College of Industrial Technology), Andrew Brenner(The University of Texas at San Antonio Health Science Center), Samaya Rajeshwari Krishnan(The University of Texas at San Antonio Health Science Center), Darrell W. Brann(Augusta University), Quan-Guang Zhang(Augusta University), Binoj C. Nair(Eli Lilly (United States))
Cited by 60
Related Papers
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|835
Neurotrophic and neuroprotective actions of estrogen: Basic mechanisms and clinical implications
|Steroids|2007|638
First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma
|Journal of Translational Medicine|2018|540
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
|The Lancet|2021|456
NADPH oxidase in brain injury and neurodegenerative disorders
|Molecular Neurodegeneration|2017|433